PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
32.15%
Cash & equivalents yoy growth at least 1.5x AXSM's 8.06%. Mohnish Pabrai might see this as a favorable liquidity edge, provided funds are well deployed.
No Data
No Data available this quarter, please select a different quarter.
32.15%
Cash + STI yoy ≥ 1.5x AXSM's 8.06%. David Dodd might see it as a strategic cash buffer advantage. Evaluate deployment plans.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
30.78%
≥ 1.5x AXSM's 9.33%. David Dodd might see a short-term liquidity advantage or potential underutilized capital.
-2.88%
0.75-0.9x AXSM's -3.54%. Bill Ackman questions if competitor invests more heavily in future capacity.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.86%
Below half of AXSM's 30.57%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
30.51%
≥ 1.5x AXSM's 9.43%. David Dodd notes a larger balance sheet expansion. Confirm it's not overleveraged.
63.16%
Above 1.5x AXSM's 5.52%. Michael Burry questions if payables are being stretched to avoid short-term borrowing.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-28.70%
Higher Other Current Liabilities Growth compared to AXSM's zero value, indicating worse performance.
49.30%
Above 1.5x AXSM's 6.46%. Michael Burry sees a red flag for liquidity risk vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
49.30%
Less than half of AXSM's 147.07%. David Dodd sees far fewer liability expansions relative to competitor.
16.87%
Above 1.5x AXSM's 0.05%. Michael Burry suspects heavy new equity expansion or dilution.
-5.16%
Below half AXSM's -18.18%. Michael Burry suspects major net losses or high dividends vs. competitor.
-13.18%
Less than half of AXSM's -100.00%. David Dodd sees fewer intangible or market-driven swings than competitor.
No Data
No Data available this quarter, please select a different quarter.
26.52%
Below half AXSM's -269.04%. Michael Burry sees potential underperformance in building shareholder capital.
30.51%
Below half AXSM's -188.78%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-32.15%
Less than half of AXSM's 20.68%. David Dodd sees better deleveraging or stronger cash buildup than competitor.